Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
... Malignancies reported through week 104 included basal
cell skin cancer (one patient), colon cancer (one ... patient) in patients receiving SIMPONI 50 mg, and basal
cell skin cancer (three patients), prostate ... reported through week 104 consisted of two basal
cell skin cancers (one patient on SIMPONI 100 mg, ...
FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
... be used in combination with a longer-acting or basal
Apidra(R) can also be used in insulin ... insulin
glargine once daily or NPH twice daily as basal
insulin. The majority of
the patients received ... after the start of a meal. Along with
exercise, a basal
insulin, and a proper meal plan, Apidra(R) is ...
Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin
... (pramlintide acetate) injection with basal
insulin therapy for 24
weeks resulted in more ... to
the use of rapid-acting insulin (RAI) with basal
insulin in patients with
type 2 diabetes. The ... rapid-acting insulin when either was added to basal
treatment in this study, with SYMLIN use ...
New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes
Patients with type 2 diabetes using basal
insulin without bolus insulin
(N=35) were ... blood glucose targets during a
period (12 p.m. to 6 a.m.). No food was eaten between 6
p.m. to ~7 a.m. in order to obtain accurate basal
New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients' Blood Sugar
... administered before 1 meal, 2 meals or 3 meals daily, already taking basal
insulin, Lantus(R) (insulin glargine [rDNA origin] injection), with or ... were not statistically significant between groups.
"By combining basal
insulin Lantus(R) plus Apidra(R) mealtime insulin at one, two or three ...
Major State Grant Accelerates Research and Development of Novel Cancer Therapy
... in the world. The two
most common types of non-melanoma skin cancers are basal
cell carcinoma and
squamous cell carcinoma (SCC). One in five Americans ... which are more effective in
treating actinic keratosis, and potentially basal
cell carcinoma and
squamous cell carcinoma," said Chakoff.
deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer
... traits also associated with risk of
cutaneous melanoma (CM) and basal
cell carcinoma (BCC). CM is the most
dangerous form of skin cancer, while ... 'ASIP and TYR pigmentation variants associate with
cutaneous melanoma and basal
cell carcinoma,' are published today in the
online edition of Nature ...
Evotec's EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks
... the changes in local cerebral blood flow.
Analysis of the changes in basal
regional cerebral blood flow indicated
a selective increase in blood flow ... considered to be significant for
indications such as pain and depression. basal
blood flow in other brain
areas was unaffected.
These findings represent ...
First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center
... cured. While melanoma is the most serious form of skin cancers, it accounts for less than 10 percent of all cases. Non-melanoma skin cancers, such as basal
cell carcinoma and squamous cell carcinoma, represent the majority of all new cases.
"We are dedicated to bringing the most complete and ...
5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH
... 5-year, randomized (1:1), multicentre, stratified, parallel-group study comparing patients treated with either twice-daily NPH (n=509) or once-daily basal
The main objective of this study was to compare the progression of diabetic retinopathy between treatment groups by analyzing ...
MJFF's Rapid Response Innovation Awards Hit Mid-2009 With Over $1 Million Funded in High-Risk/High-Reward Approaches to Parkinson's Disease
... MJFF funding, they are working in a pre-clinical model of PD to assess the practical potential of modifying abnormal synchronization in the brain's basal
ganglia region -- an approach that, according to preliminary theoretical studies, could result in functional improvements for PD patients.
Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients
... two 52-week studies show that the investigational ultra rapid acting insulin AFRESA(R) (insulin human [rDNA origin]) Inhalation Powder combined with basal
insulin is comparable to standard of care therapies in controlling post-meal blood sugar levels, and also results in significantly less weight gain ...
Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinson's Disease
... neural stem cells, multiply them in vitro and ultimately
differentiate them to produce mature neurons before they are reintroduced into
the brain's basal
ganglia. This is performed without the patient requiring
immunosuppressants. Of particular note are the striking results this study
yielded -- for ...
Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial
... in extreme cases, a loss of physical movement (akinesia).
The primary symptoms are the results of decreased stimulation of the motor
cortex by the basal
ganglia, normally caused by the insufficient formation and
action of dopamine, which is produced in the dopaminergic neurons of the
brain. Secondary ...
ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
... strong trend for ecabet sodium, which approached statistical significance versus placebo. This result is important because it indicates an effect on basal
tear secretion, which is one of the main factors in the etiology of dry eye disease. In addition, the percentage of patients who responded to ecabet ...
A Milestone in Cancer Genetics: deCODE Discovers First Common Genetic Variants Affecting the Risk of Many Types of Cancer
... CEO of deCODE and senior author on the
deCODE discovered the first variant, a SNP called rs 401681, in its gene
discovery work on basal
cell carcinoma (BCC), a common form of skin cancer.
The SNP is in the gene encoding cisplatin resistance related protein 9
(CLPTM1L). Because the ...
Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
... considered a gold standard for
patients with late stage type 2 diabetes who have difficulty achieving
glycemic targets with oral medications and/or basal
explained study author Andreas Fritsche, MD, IVth Medical Department,
University of Tübingen, Germany.
When compared to pre-mixed ...
Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes
... common in the Carb Counting group than in the Simplified Algorithm
group (8.0 vs. 4.9 events/patient-year, P=0.02).
"A combination of basal
and bolus insulin may be needed to achieve
optimal glucose control in type 2 diabetes patients," explained study
author Richard M. Bergenstal, MD, ...
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
... developed breast
cancer, one patient taking golimumab 100 mg plus placebo developed Bowen's
disease and one patient taking placebo plus MTX developed basal
carcinoma. There were no reports of opportunistic infection or
About the GO-BEFORE Trial
GO-BEFORE, a Phase 3, multi-center, ...
DURABLE Clinical Trial Results Show GlycoMark is Key Test for Managing Patients with Diabetes
GlycoMark to reflect after-meal glucose levels with 2,094 patients enrolled
from 11 countries. The DURABLE trial (Assessing the Durability of basal
Lispro Mix 75/25 Insulin Efficacy) confirms results from a smaller
population study completed by John Buse, MD (University of North ...
Study Shows Lantus(R) Helped People Living with Type 2 Diabetes Reach the ADA's Recommended Target for Blood Sugar Control
... Lantus(R) when
Initiated Promptly in patients with type 2 diabetes) clinical study, 66
percent of patients who began treatment with the long-acting, basal
Lantus(R) (insulin glargine [rDNA origin] injection) achieved A1C <7%, the
ADA's recommended target for glycemic control, while only 38 ...
Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
... Cancer Research (AACR) Annual Meeting in San Diego, CA.
The study, conducted in mouse models of oral mucositis, showed that
NU206 regenerated basal
layer epithelial cells and accelerated cell repair
by stimulating the Wnt pathway, a signaling pathway that is critical for
cell growth and ...
Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R)
... About Apidra(R)
Apidra(R) works fast and offers flexible insulin dosing to help manage
mealtime blood sugar levels. Along with exercise, a basal
insulin, and a
proper meal plan, Apidra(R) is proven to help reduce A1C levels in adults
with type 1 and type 2 diabetes. Apidra(R) can be ...
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
... in five
percent of patients receiving golimumab and three percent of patients
receiving placebo. One case of prostate cancer and two cases of basal
carcinoma were reported in golimumab-treated patients. There were no
reports of tuberculosis or opportunistic infections through week 24. About ...
First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
... 1982. Gewirth's research is focused primarily on
structural studies of HSP90 chaperones, drug design, protein folding;
nuclear hormone receptors; and basal
transcription factors. Gewirth and his
wife live in Buffalo. About HWI With more than 50 years of exceptional scientific research, HWI is ...
Saving Lives of California Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment
... Dr. Gross at Skin
Surgery Medical Group specializes in the following: skin cancer diagnosis
and treatment including but not limited to melanoma, basal
squamous cell cancer; diagnosis and treatment of moles and melanoma
including sentinel node biopsy of lymph nodes; Mohs Surgery of skin ...
The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
... segmental body composition test measures lean body mass, total body water, and percent of body fat. (2) The calorimetry determines the body's basal
metabolic rate or resting energy expenditure and locates a weight management zone. (3) The patient wears a multisensor arm band 5-10 days at ...
Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
... in the incidence of adverse events. The efficacy of ENDOMETRIN was also evaluated in harder-to-treat
patients - women over age 35 or with elevated basal
hormone (FSH) or body mass index (BMI). Excellent continuing pregnancy
rates were observed across a broad range of patient types ...
New Data Confirm That Use of Levemir Can Limit Weight Gain
... published where it has been compared to
insulins.(10-23) Collectively these trials ... (insulin analogue)
that covers the body’s basal
insulin needs. Levemir® is
released gradually ... NPH insulin in patients with type 1 diabetes on a basal
regimen with premeal insulin aspart. ...
New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes
Using Self-Adjusted Dosing Starting With Once-Daily Insulin
... Levemir(R), as
patients were able to adjust their basal
insulin dose on their own
and achieve the same ... analogs like Levemir(R), which provide
insulin coverage, and, as shown in this study, ... insulin to show less weight gain versus
insulins in 12 of 12 controlled clinical ...
New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes
Using Self-Adjusted Dosing Starting With Once-Daily Insulin
... patients were able to adjust their basal
insulin dose on their
own and achieve the same ... like
Levemir®, which provide effective basal
insulin coverage, and,
as shown in this study, ... insulin to show less weight gain versus
insulins in 12 of 12 controlled clinical trials*. ...
Generex Biotechnology to Make Presentations At 46th Annual Meeting
of the European Society of Pediatric Endocrinology
... Administered at Lunchtime in Juvenile Type-1
DM Subjects Maintained on basal
Glargine Insulin and Pre-Breakfast
and Pre-Dinner Regular Insulin, by ... Insulin (Generex Oral-lyn(tm)) In Adult
Type-1 DM Subjects Maintained on basal
S.C. BID Isophane Insulin
(NPH), by Doctors Jaime Guevara-Aguirre, Marco ...
AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical
Pipeline to Be Featured at AACR
... (p110alpha)" - Poster Session:
Mouse Models of Cancer - Section 21, Board 4
-- Tuesday, April 17, 2007 at 8:00 a.m. to 12:00 p.m. "Novel
type breast cancer models generated through genetic
manipulation of normal human breast tissue in mice" - Poster
Session: Mouse Models of Cancer - ...
Ferring Reports on ENDOMETRIN Presentations at Pacific Coast
Reproductive Society Annual Meeting
... Results in Harder-to-Treat Patients
The activity of ENDOMETRIN was also evaluated in harder-to-treat
patients - women over age 35, or with elevated basal
stimulating hormone (FSH) or body mass index (BMI). Excellent
continuing pregnancy rates were observed across a broad range of
patient types ...
Phase III Data on Safinamide in Parkinson’s Disease Presented
at American Academy of Neurology 59th Annual Meeting
... in extreme cases, a loss of physical movement (akinesia). The
primary symptoms are the results of decreased stimulation of the
motor cortex by the basal
ganglia, normally caused by the
insufficient formation and action of dopamine, which is produced in
the dopaminergic neurons of the brain. Secondary ...
Solstice Neurosciences Presents Escalating Dose Study at
International Congress in Istanbul, Turkey
... dystonia requiring referral to movement disorder clinics.
While the exact cause of CD is unknown, scientists believe the
problem originates in the basal
ganglia area of the brain that is
instrumental in movement. In general, there are three main
approaches to the treatment of CD: oral medications, ...
Amylin Pharmaceuticals to Present New Data from Broad Diabetes and
Obesity Programs at ADA 2007
... PM ET).
4. Poster: "Pramlintide Improved Glycemic Control without Increased Risk
of Hypoglycemia in Patients with Type 2 Diabetes Using basal
will be presented by Karen Lutz, Ph.D. during a poster session on
Sunday, June 24 at 12:00 PM CT (1:00 PM ET).